• 11/27/2024

Merck MS Drug Misses Late-Stage Trial Target

Wall Street Journal

Merck KGaA’s shares fell around 13% after its multiple sclerosis drug evobrutinib didn’t meet a key goal in late-stage trials.

https://www.wsj.com/articles/merck-ms-drug-fails-to-meet-target-of-late-stage-trials-3bb8225d